Fennec Pharmaceuticals Inc. Overview
Pro stress-test →Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. PEDMARK was commercially launched in the United States in October 2022 and has since achieved significant market traction. The company addresses a critical unmet medical need for children receiving cisplatin chemotherapy who face permanent hearing loss.
Strategic Profile
Pro stress-test →PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. In March 2026, the company settled PEDMARK patent litigation with Cipla, which restricted generic entry until September 1, 2033, providing substantial market exclusivity. The company has focused on expanding PEDMARK's clinical and commercial footprint, including investigator-initiated studies and real-world evidence generation.
Competitive Landscape
Pro stress-test →PEDMARK provides the first and only FDA-approved treatment specifically designed to help protect hearing in children and young adults after receiving cisplatin. As a first-to-market orphan drug with exclusive indications, Fennec faces limited direct competition in the pediatric ototoxicity protection space. However, the company competes broadly within the oncology supportive care market and faces potential competition from off-label use of generic sodium thiosulfate.
Industry Context
Fennec Pharmaceuticals Inc. operates in Biotechnology / Specialty Pharmaceuticals.
Key facts
Founded: 1996 · Headquarters: Research Triangle Park, North Carolina